In October 2026, Nuance Pharma announces the first patient dosed in the REACH Phase III trial, a randomized, double-blind, ...
Lynk Pharmaceuticals Expands Simcere Partnership to Commercialise Zemprocitinib for Atopic Dermatitis in Greater China ...
Over 70% of patients achieved PASI 90 and more than 80% reached PGA 0/1 at Week 16, demonstrating significant efficacy over placebo with no new safety signals.
Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral ...
Backed by GSK, Pfizer and Sanofi, the Cascade initiative will integrate single-cell sequencing and protein data to strengthen ...
Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive ...
Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide ...
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple ...
TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours ...
Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial ...
Despite missing primary endpoints, the endocannabinoid modulator demonstrated encouraging pain score improvements in subgroup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results